NORSE

Age-related Macular Degeneration // Clinical Trials // Mihai Mititelu // Ongoing // Sep 30 2020

A clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (NORSE)

  • Sponsor: Outlook Therapeutics, Inc
  • Principal Investigator: Mihai Mititelu, MD, MPH
  • Study Coordinator: Nickie Stangel

Study objective:

This study will evaluate the safety, efficacy, and tolerability of ONS-5010 as compared with ranibizumab.

Study design:

Study participants will be randomized into 2 study groups to receive ONS-5010 or 0.5 mg ranibizumab injections.

Diagnosis and Key Eligibility Criteria:

Male or females ages ≥50 years with active primary subfoveal CNV lesions secondary to AMD in the study eye. Patients receiving anti-VEGF treatment for AMD in the fellow eye are eligible for enrollment in the study. Previous use of anti-VEGF or Avastin in the study eye is not allowed.

Duration of study: Approximately 5 years

For more information, contact Nickie Stangel 608-263-8783